Good joining you update. us for morning thank and for our quarterly
which in These progress in have well ago a but antibodies speak made of the that PD-X two about we which a been discoveries to are CTLA-X. conscious very of had programs, we as few past have treatment in productive I and target These decision have clinic. summary As in including these substantial the will today. years cancer will as minutes, more immuno-oncology enter backbone antibodies, are the become years, pursue several the in about detail, made we to number clinical you substantial next see several new our several the have the months.
the into combinations. clinic individually and them have We advanced in
cell to portfolio at year. we responses, treated believe of plan believe will this with year, vaccines, important role in we speed backbone of innovation regulatory ASCO with novel the combinations and and including planned But play six these thus our we observed five patients number this accomplished two of over filed the first them, months, of we antibodies, be with XXX have critically far have also and another a be basis neoantigen what year. achieve filed How We the our and next approvals. we they past to and of have therapies. business pursuing XX on additional track combinations on are are So an INDs model presented which important will INDs INDs one half immuno-oncology molecules far, in
that the Our gen susceptible IND attack. roster more modifiers bispecific includes next for antibodies approaches. Tumor desirable microenvironment tumor this immune to in make modify are order to year the most tumor amongst immuno-oncology microenvironment the
We desirable have two antibodies uniquely at with properties. least
first IND I addition expect next cell also company its for therapy to mentioned, In cell we AgenTus INDs file therapy to year. our the
Next, from range don't larger These companies. to potentially several various product update, development deals I discussions provide much have advancing with yet, partnership I announceable a just discussions while will licensing are an collaborations.
entering program, our antibodies own in will soon. checkpoint neo-antigen has cancer which received as year. Also with our are are Merck the months. component be QS-XX the existing three closure some payments and expectations and we will that respect this additional milestone all programs two to to available adjuvant With Our payable most stimulant also increasing bring an enabling interest potent date. combination is very to Incyte to including next be the advancing with vaccine within them clinic our expect QS-XX with partnership progress of to
year. $XXX As first you're to earlier years were vaccine as same is three end last was Shingrix in the is Shingrix revised Merck's approval with the times revenues full Shingrix, XX about XX% year, what year a year same in this year, is have to expected efficacy. million of recently most at Zostavax shingles the last aware, received component of the tracking world's GSK's revenue they called QS-XX over the and after about in it which top market. the efficacious key been year's estimates this
Our which has due royalty payments revenue milestone additional transaction are this to achieved. are totaling $XX if revenue milestones year announced million, Agenus earlier specific
than and we antibodies our patients have activity recently. year, PD-X our AGEN-XXXX. update To- as clinical will on with said data Last with combination I antibody CTLA-X PD-X targeting more date, I antibodies AGEN-XXXX AACR our provide with clinical anti-CTLA-X our proprietary own antibody programs. and launched CTLA-X anti-PD-X research presented treated Now in combinations. and we targeting under you an separately We our XXX of and of at compelling pharmacodynamic trials
be at clinical this earlier, there our will advanced data mentioned I and cancer significant complete we cancers. plan and We seen targeting represent we antibodies in with current our Agenus. players, Very PD-X a for antibodies. presented ASCO cell develop, recently, have cancer. opportunity and approval of shifted antibodies. Hence and partial that as commercial aggregate CTLA-X with CTLA-X from both patient are the responses cervical register, be billion. non-small these to of believe to to both we our lung PD-X mentioned compounds, As launch first on trials This $XX year, year, In I revenue despite strategy antibodies our for expected
with also improved of set two used for future as of standard cell chemo lung combination -- which the an care, important lung or for cancer We radiation. combination has strategy data with crowded reasons when has cancer. combination cancer, driver emerged the higher increasingly own first-line include opportunities in any approvals. recent our cervical our efficacy PD-X in Merck’s Keytruda chemotherapy bar of with and in will developing shift our be antibodies The non-small of for
and combinations such PD-X exploring own CTLA-X opportunistically our antibodies. are with We
We PD-X our acquired readiness launch it we provide commercial California successfully grade proved three clinical manufacturing our efforts, facility programs and We us have have of supplied today. and combination get with Also, antibodies. has continue CTLA-X years antibodies. to ago manufactured commercial PD-X our and efficient proprietary year with triple I this our studies capabilities lastly we're CLTA-X before planning our into speedy and vaccine independent, manufacturing cost our pipeline, in both combination and
clinical antibodies pipeline expected the clinic I immuno-oncology in So to I to registration have touched agents of clinic, discussed of plans. the are far, future will product exciting our now our our enter on shift slate and and a soon. which
as With year. to and that, and year on INDs half market time intratumoral agents These and also have INDs this as current field overcoming CTLA-X beating the to successfully shortly. INDs B-cell bispecific the track additional the I additional discovered in this novel the selectively environment to deplete is solid we compounds Amongst that regulatory two to well rigs are the in file earlier, mythological the next IND are CTLA-X, is We for next these be tumor importantly six We're timing. feature, gen increasing Agenus' this believe Our novel pipeline of expert escape further. lymphoma. scientist improve is a T T are filings gen mechanism like antibodies These advancing treatments condition as well published numbers as and an address two our mechanisms of T-cell first our treatment year. T-cells could critical molecules. is expand and others findings the immuno-oncology current as depleting deplete limitations designed this CTLA-X of or significantly. our rigs T mentioned design bispecific expected tumor in our planning micro enhances today rigs the next We that this -- tumors believe of for function tumors to
production. spite presented potential significant and all therapy has to you Summit has and at current and very value shareholders. approaches our well limitations. life-saving company AgenTus that including limitations the patients created this Boston. are shown PEGS cell these as Last In for therapy Lastly, address challenges in week We manufacturing cell have for know logistical costs and known of of Hurwitz Dr. technologies believe capabilities potentially high has
designed libraries receptors tumors. quality Specifically receptors, generated solid our those T-cell high proprietary platform has target to of
our costs. and logistical designed challenges, is as cell format manufacturing scalability as allogeneic well to In address addition,
We proprietary library exciting our It a targeting with phosphorylated of an very targeting and cell have mechanism is optimize designed also therapy. for efficacy off shelf to mechanism both safety, targets vaccines potentially as well. the improved with
discovery us therapy the gives acquisitions and includes which and environment team. business advantages in-house, One de-novo structural to possess core field history bio-informatics, bispecific and given to most access programs and in develop pipeline rapidly we extraordinarily biology, which of point ability conditioning all molecular long four our capabilities of with key In made micro are rapidly. of and innovate validated past These our cancer summary, of agents capabilities a computational importantly combinations. check talented very to immunotherapy cell in platforms, the first-in-class years, the and along in biology for our the the antibodies we’ve advance tumor cell compelling
one months. importantly, generated We enter which transformed company and opportunities advancing clinic those next with XX capabilities to field. have the our a XX extensive Agenus the the into of in our in generation pipeline have Also exciting to the next beyond pipelines now are most stated exciting
to believe mechanisms for As accomplish tumor the modify this. such we micro-environment successful be and I cures that the amongst the products drivers experts next cancer. believe best alluded the to believe earlier, We generation as also and treatment ability we have of other to new will
our antibodies, capabilities are look to advantages have pipeline our provide we discussions been are to time immuno-oncology and and much ability field, these We our addition with the vaccines, rare. and in knowledge our Increasing companies, which very Thank of us our drivers In partnership these antigen molecules for therapies immuno-oncology of at which first interest Christine? very questions key our with of the in new company. you conclusions interest in generation discussion. combine cell to-date. unique the your your forward from adjuvant
